Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
In This Section
More Information
Health in the Landscape of Life
Enabling the healthscape, the ecosystem outside the clinic, requires improving the system to pay for health drivers.
More Information
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
More Information
Make an Appointment Give Faculty Students Alumni Directory

Psychiatry & Behavioral Sciences Grand Rounds: Bipolar Disorder Center & a Seven Year Update

Location: Health Discovery Building Auditorium (HDB 1.208)

Address: 1601 Trinity St., Bldg. B, Austin, Texas 78712 | View Map »

Date: Tuesday, May 28, 2024

Time: 12–1:30 p.m.

Contact: Jennifer Braham

About the Event

In this installment of Psychiatry and Behavioral Sciences Grand Rounds, Jorge Almeida, M.D., Ph.D., presents “Bipolar Disorder Center: A Seven Year Update.” Almeida is the director of the Bipolar Disorder Center at UT Health Austin and an associate professor in the Department of Psychiatry and Behavioral Sciences at Dell Medical School.

For more information about the event, email Jennifer Braham.

Upon request, Dell Medical School will provide interpretation services at this event. Please notify Jennifer by May 1, 2024, if interpretation is needed.

Learning Objectives

By the end of this presentation, the audience participant should be able to:

  1. Review the bipolar disorder integrated practice unit (IPU) application leading to value-based care at Dell Medical School.
  2. Identify opportunities to work collaboratively with community partners to achieve higher bipolar disorder care that is cost-saving.
  3. Determine opportunities to decrease the gap between cutting-edge research informed by clinical practice:
    1. Identify potential use for Stanford Accelerated Intelligent Neuromodulation Therapy using transcranial magnetic stimulation (TMS) in bipolar depression;
    2. Identify brain imaging markers in bipolar disorder offspring;
    3. Explore the impact of photobiomodulation on bipolar disorder cognition and brain function.

Target Audience

  • Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
  • Secondary: Other health care professionals


This activity has been designed to promote some of the following desired physician attributes and competencies:

  • ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice.
  • IOM: Provide patient-centered; Work in interdisciplinary teams; Employ evidenced-based practice; Apply quality improvement; Utilize informatics
  • IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice

Speaker Disclosure

Jorge Almeida, M.D., Ph.D., speaker for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Planner Disclosure

Mark H. Townsend, M.D., M.S.; Carol L. Alter, M.D.; Lloyd S. Berg, Ph.D., ABPP; Octavio N. Martinez Jr., M.D., MPH; and Jennifer Braham, M.S., planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/research support from Navitor Pharmaceuticals and Sage Therapeutics, and he is a consultant for Sage Therapeutics. He received an honorarium for serving on the advisory board of Sage Therapeutics, Merck and Janssen.

Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Signant Health, Janssen Research & Development LLC, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Bioscience LTD, EcoR1 Capital LLC, EmbarkNeuro (formerly AncoraBio), Galen Mental Health LLC, Goodcap Pharmaceuticals Inc., ITI Inc., LUCY Scientific Discovery, Relmada Therapeutics Inc., Sage Therapeutics, Senseye Inc., and Precisement Health. He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Precisement Health, and Relmada Therapeutics Inc. Nemeroff is on the scientific advisory boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR) Inc., Galen Mental Health, LLC, Heading Health, LLC, Pasithea Therapeutics Corp, Sage Therapeutics, Inc and Senseye, Inc. He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

The CME Advisory Committee, reviewers of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

All the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas at Austin Dell Medical School designates this live course for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.